Jiangsu Aidea Pharmaceutical , Ltd. Receivables

As of the most recent data (June 2026), 688488.SS shows a receivables of $210M. That compares with $200M in the prior-year period — up 7.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 688488.SS's receivables is now $210M (was $200M) — a 7.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Jiangsu Aidea Pharmaceutical , Ltd. is outperforming or lagging.

Tracking 688488.SS's receivables over time shows whether Jiangsu Aidea Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $210M That compares with $200M in the prior-year period — up 7.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Jiangsu Aidea Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $210M) with ownership activity and broader fundamentals.

Jiangsu Aidea Pharmaceutical , Ltd.'s receivables is $210M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.